Incyte Corp. (INCY): Price and Financial Metrics

Incyte Corp. (INCY): $58.10

0.71 (-1.21%)

POWR Rating

Component Grades








Add INCY to Watchlist
Sign Up

Industry: Biotech




#7 of 359

in industry

INCY Price/Volume Stats

Current price $58.10 52-week high $86.29
Prev. close $58.81 52-week low $57.91
Day low $57.91 Volume 2,306,800
Day high $59.34 Avg. volume 1,767,047
50-day MA $63.57 Dividend yield N/A
200-day MA $70.71 Market Cap 13.02B

INCY Stock Price Chart Interactive Chart >


  • Quality is the dimension where INCY ranks best; there it ranks ahead of 97.98% of US stocks.
  • The strongest trend for INCY is in Value, which has been heading up over the past 179 days.
  • INCY ranks lowest in Momentum; there it ranks in the 16th percentile.

INCY Stock Summary

  • INCY has a market capitalization of $13,335,458,729 -- more than approximately 86.76% of US stocks.
  • The ratio of debt to operating expenses for INCYTE CORP is higher than it is for about merely 5.32% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.31 for INCYTE CORP; that's greater than it is for just 17.93% of US stocks.
  • If you're looking for stocks that are quantitatively similar to INCYTE CORP, a group of peers worth examining would be ABEO, ADAP, LNTH, SABS, and PTN.
  • Visit INCY's SEC page to see the company's official filings. To visit the company's web site, go to

INCY Valuation Summary

  • In comparison to the median Healthcare stock, INCY's price/earnings ratio is 33.58% higher, now standing at 36.4.
  • INCY's price/sales ratio has moved down 1.8 over the prior 243 months.

Below are key valuation metrics over time for INCY.

Stock Date P/S P/B P/E EV/EBIT
INCY 2023-09-18 3.8 2.8 36.4 18.2
INCY 2023-09-15 4.0 3.0 38.2 19.5
INCY 2023-09-14 4.0 3.0 38.8 19.8
INCY 2023-09-13 4.0 3.0 38.6 19.7
INCY 2023-09-12 4.1 3.0 39.3 20.1
INCY 2023-09-11 4.1 3.0 39.4 20.2

INCY Growth Metrics

    Its 3 year revenue growth rate is now at 55.94%.
  • Its 2 year revenue growth rate is now at 39.71%.
  • Its 3 year net income to common stockholders growth rate is now at 268.87%.
INCY's revenue has moved up $1,165,226,000 over the prior 34 months.

The table below shows INCY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,394.635 969.941 340.66
2022-09-30 3,330.788 801.63 876.05
2022-06-30 3,320.472 760.347 945.014
2022-03-31 3,114.784 759.134 933.038
2021-12-31 2,986.267 749.488 948.581
2021-09-30 2,912.923 741.458 534.58

INCY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INCY has a Quality Grade of A, ranking ahead of 95.94% of graded US stocks.
  • INCY's asset turnover comes in at 0.76 -- ranking 198th of 563 Business Services stocks.
  • TSSI, APDN, and NUAN are the stocks whose asset turnover ratios are most correlated with INCY.

The table below shows INCY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.760 0.951 0.546
2021-06-30 0.754 0.949 0.381
2021-03-31 0.787 0.951 0.523
2020-12-31 0.831 0.951 -0.231
2020-09-30 0.774 0.948 -0.298
2020-06-30 0.758 0.949 -0.138

INCY Price Target

For more insight on analysts targets of INCY, see our INCY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $102.47 Average Broker Recommendation 1.56 (Moderate Buy)

Incyte Corp. (INCY) Company Bio

ncyte is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. (Source:Wikipedia)

INCY Latest News Stream

Event/Time News Detail
Loading, please wait...

INCY Latest Social Stream

Loading social stream, please wait...

View Full INCY Social Stream

Latest INCY News From Around the Web

Below are the latest news stories about INCYTE CORP that investors may wish to consider to help them evaluate INCY as an investment opportunity.

3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall

Even with higher for longer interest rates, drug discovery moves on.

Chris Markoch on InvestorPlace | September 20, 2023

13 Best Beaten Down Stocks To Buy Now

In this article, we will be taking a look at the 13 best beaten down stocks to buy now. To skip our detailed analysis of the US stock market and recent developments within it, you can go directly to see the 5 Best Beaten Down Stocks To Buy Now. The Two-Day Fed Meeting On September […]

Yahoo | September 20, 2023

Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival

Incyte stock tumbled to a nearly five-year low Monday after GSK gained FDA approval for a rival myelofibrosis treatment.

Yahoo | September 18, 2023

Unveiling Incyte (INCY)'s Value: Is It Really Priced Right? A Comprehensive Guide

An In-depth Analysis of Incyte (INCY)'s Intrinsic Value and Market Position

Yahoo | September 18, 2023

FDA approves GSK's unique myelofibrosis treatment Ojjaara

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.

Yahoo | September 18, 2023

Read More 'INCY' Stories Here

INCY Price Returns

1-mo -9.54%
3-mo -6.97%
6-mo -17.95%
1-year -13.14%
3-year -32.42%
5-year -12.61%
YTD -27.66%
2022 9.43%
2021 -15.61%
2020 -0.39%
2019 37.32%
2018 -32.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!